Highlights ChromaDex Corporation

Equities

CDXC

US1710774076

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
3.56 ^USD	+3.49%		+20.68%	+148.95%

Apr. 23	Chromadex Announces Inaugural Major Grocery Debut of Tru Niagen® At Sprouts Farmers Market	CI
Apr. 09	Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chromadex Announces Inaugural Major Grocery Debut of Tru Niagen® At Sprouts Farmers Market	Apr. 23	CI
Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q4 Revenue $21.2M, vs. Street Est of $20.7M	Mar. 06	MT
ChromaDex Corporation Provides Earnings Guidance for 2024	Mar. 06	CI
ChromaDex Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
ChromaDex Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Neurohacker Collective and Chromadex Partner to Optimize Cellular Health with the Debut of Qualia Nad+	Dec. 12	CI
Ch ChromaDex Corp. shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson's disease (PD)	Nov. 30	CI
Chromadex Corp. Shares Results from Phase II Clinical Study	Nov. 15	CI
Earnings Flash (CDXC) CHROMADEX CORPORATION Posts Q3 Revenue $19.5M, vs. Street Est of $20.4M	Nov. 08	MT
ChromaDex Corporation Provides Revenue Guidance for the Year 2023	Nov. 08	CI
ChromaDex Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
ChromaDex Launches New Food Supplement	Nov. 01	MT
ChromaDex Corp. Debuts Clinical Strength Tru Niagen®? Pro 1,000Mg Featuring Niagen®? (Patented Nicotinamide Riboside)	Nov. 01	CI
ChromaDex Corp. and Zesty Paws Crack the Code on Cellular Health for Dogs With ?Healthy Aging? Line	23-10-26	CI
Chromadex Announces Results from Newly Published Clinical Study, as Reported in the Peer-Reviewed Journal Cell Reports, Demonstrating That Supplementation with Nicotinamide Riboside	23-10-02	CI
Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q2 Revenue $20.3M, vs. Street Est of $19.5M	23-08-09	MT
ChromaDex Corporation Provides Revenue Guidance for the Year 2023	23-08-09	CI
ChromaDex Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Chromadex Corp. Launches Tru Niagen with Iherb	23-08-08	CI
ChromaDex Corp. Announces Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide in Glaucoma Patients and That Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects	23-07-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ChromaDex Corporation

Equities

CDXC

US1710774076

Highlights

Filters